Submission of Matters to a Vote of Security Holders

Filing Summary

Registrant: Galecto, Inc. The request metadata identifies Damora Therapeutics, Inc., but the filing names Galecto, Inc. as the registrant.

Reporting event: Current Report on Form 8-K filed June 15, 2023, reporting matters voted on at the annual meeting held June 14, 2023. The filing concerns corporate governance and auditor ratification, not operating or financial results.

Business Context and Period

Galecto is a Delaware corporation whose common stock trades on The Nasdaq Global Select Market under the symbol GLTO. The company reported the results of its 2023 annual meeting of stockholders.

Financial Metrics and Liquidity

The filing does not provide revenue, profit or loss, cash flow, margin, debt, liquidity, guidance, or other operating financial metrics.

Material Changes and Meeting Results

  • Jayson Dallas, M.D., Amit Munshi, and Hans Schambye, M.D., Ph.D. were elected as Class III directors to serve until the 2026 annual meeting, subject to earlier death, resignation, or removal.
  • EY Godkendt Revisionspartnerselskab was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
  • Shares entitled to vote: 25,673,474; shares present or represented by valid proxy: 16,122,362.
ProposalForAgainstWithheld/AbstainedBroker Non-Votes
Jayson Dallas, M.D.9,917,146—696,399 withheld5,508,817
Amit Munshi10,526,701—86,844 withheld5,508,817
Hans Schambye, M.D., Ph.D.10,508,799—104,746 withheld5,508,817
Auditor ratification16,042,72552,66126,976 abstainedNone

Guidance, Risks, and Unusual Items

The filing provides no management guidance, outlook, risk update, contingencies, or unusual financial items. The primary disclosure is the potential entity-name discrepancy between the request metadata and the filing itself.

Investor Verification Items

  • Verify that Galecto, Inc., rather than Damora Therapeutics, Inc., is the intended registrant.
  • Confirm the elected directors’ continuing service and board committee assignments in subsequent filings.
  • Review later filings for the company’s fiscal-year 2023 financial results, liquidity position, auditor reports, and any changes in corporate status.
  • Confirm the auditor’s appointment and independence disclosures in the company’s subsequent periodic filings.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.